[Dalfampridine (ampyra) in multiple sclerosis patients]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Regueiro A, Alcaraz A, Valanzasca P, Elorriaga N, Romano M, Rojas J
Record ID 32011000977
Spanish
Authors' objectives:
To evaluate efficacy and safety of Ampyra in people with ambulatory deficits due to MS.
Authors' recommendations:
The results from the recently published Phase II and III studies with 10 mg dalfampridine twice daily in MS patients in which walking is affected, showed that treatment results in a significant improvement in walking compared to no treatment, in a subgroup of MS patients (18-70 years, T25FW in an average time of 8 to 60 seconds). Although the improvement is mild, with questionable objective clinical markers and improvement parameters, from the patient\\\'s subjective perspective, improvements have been significant and important; therefore its use should be carefully considered.
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=1215&origen_publicacion=publicaciones
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Multiple Sclerosis
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.